Autolus Therapeutics plc

NASDAQ:AUTL

Biotechnology

Healthcare
$1.09 +0.33%

+$0.01 today

Market cap
$290.12M
Beta
2.01
P/E (TTM)
-1.4
EPS (TTM)
-$1.09
52W Low $1.18High $2.70

Volume 2.10M

Average 1.60M

Returns on capital

Autolus Therapeutics plc management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-161.8%

avg -65.2%

ROIC

-51.5%

avg -46.1%

ROA

-48.9%

avg -34.9%

Analysis

ROA is currently the strongest return metric at -48.9% versus its period average of -34.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Christian Martin Itin

Chief Executive Officer & DirectorUSD 2.68M62——

Chris Williams

Senior VP & Chief Business Development Officer—46——

Martin Pule MBBS

Founder, Senior Vice President & Chief Scientific Officer—54——

Matthias Will

Senior Vice President & Chief Development Officer—5383.30K0.03%

Alexander Swan

Senior Vice President & Chief Human Resources Officer—6116.47K<0.01%

Alex Driggs

Senior Vice President of Legal Affairs & General Counsel and Secretary—506.00K<0.01%

Christopher Vann

Senior Vice President & Chief Operating Officer—61——

Patrick McIlvenny

Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer—46——

Robert F. Dolski

Senior Vice President & Chief Financial Officer—55——

Miranda Neville

Senior VP & Chief Technology Officer—51——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 18, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

1

$15,681.57

Net Transaction Value

−$15,681.57

Net selling

Most Active

Piccina Cintia

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 2, 26

Piccina Cintia

Direct

Sell$15.7K

Summary

Insiders reported 0 buys worth $0.00 and 1 sells worth $15,681.57 over the last 12 months. That adds up to net selling of $15,681.57. Piccina Cintia was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+130.2%
+51.0% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Recent growth has been strongest in Revenue at +130.2% over three years. Forward estimates point to Revenue at +51.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Autolus Therapeutics plc compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AUTL's management, answered from reported figures.

Who manages AUTL?

Autolus Therapeutics plc (AUTL) lists 10 active executives. The top listed executive is Christian Martin Itin, Chief Executive Officer & Director.

Are AUTL insiders buying or selling?

Recent insider activity shows net buying of $719,593.43.